Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takayuki Sumiyoshi

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Cancer Medicine|October 27, 2020
Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinomaHiromasa Sakamoto, Toshinari Yamasaki, Takayuki Sumiyoshi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 4, 2026
[DEVELOPMENT OF FATAL IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED ENCEPHALITIS FOLLOWING COMBINATION THERAPY WITH PEMBROLIZUMAB AND LENVATINIB IN A PATIENT WITH CLEAR CELL RENAL CELL CARCINOMA]Daisuke Takahashi, Kimihiko Masui, Hajime Takamori, et al.
BMC Medicine|January 16, 2026
Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitorsMasashi Kubota, Satomi Yoshida, Takayuki Goto, et al.
Advances in Radiation Oncology|April 29, 2024
Spatial Pattern of Intraprostatic Recurrence after Definitive External-Beam Radiation Therapy for Prostate Cancer: Implications for Focal Boost to Intraprostatic Dominant LesionRihito Aizawa, Tomoaki Otani, Takashi Ogata, et al.
Clinical Genitourinary Cancer|July 17, 2019
Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate CancerMaki Fujiwara, Shusuke Akamatsu, Takayuki Sumiyoshi, et al.
JCO Precision Oncology|January 6, 2025
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial CancerToru Sakatani, Takayuki Sumiyoshi, Yuki Kita, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 7, 2011
[A case of renal cell carcinoma associated with paraganglioma]Takayuki Sumiyoshi, Yosuke Shimizu, Takahiro Inoue, et al.
Frontiers in Oncology|September 19, 2025
Case Report: Genomic insights into prostate adenocarcinoma transdifferentiation to carcinosarcoma due to lineage plasticityTomohiro Fukui, Arinobu Fukunaga, Yuki Teramoto, et al.
Frontiers in Oncology|April 17, 2023
Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse modelMasashi Takeda, Hiromasa Sakamoto, Noboru Shibasaki, et al.
Molecular Cancer Therapeutics|May 14, 2026
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiencyYuki Kamiyama, Takuro Sunada, Yutaka Kanoh, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Cancer Medicine|October 27, 2020
Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinomaHiromasa Sakamoto, Toshinari Yamasaki, Takayuki Sumiyoshi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|June 4, 2026
[DEVELOPMENT OF FATAL IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED ENCEPHALITIS FOLLOWING COMBINATION THERAPY WITH PEMBROLIZUMAB AND LENVATINIB IN A PATIENT WITH CLEAR CELL RENAL CELL CARCINOMA]Daisuke Takahashi, Kimihiko Masui, Hajime Takamori, et al.
BMC Medicine|January 16, 2026
Association between preoperative interruption of antiplatelet therapy and postoperative thrombotic risk after minimally invasive surgery for abdominopelvic cancer in patients treated with P2Y12 inhibitorsMasashi Kubota, Satomi Yoshida, Takayuki Goto, et al.
Advances in Radiation Oncology|April 29, 2024
Spatial Pattern of Intraprostatic Recurrence after Definitive External-Beam Radiation Therapy for Prostate Cancer: Implications for Focal Boost to Intraprostatic Dominant LesionRihito Aizawa, Tomoaki Otani, Takashi Ogata, et al.
Clinical Genitourinary Cancer|July 17, 2019
Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate CancerMaki Fujiwara, Shusuke Akamatsu, Takayuki Sumiyoshi, et al.
JCO Precision Oncology|January 6, 2025
Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial CancerToru Sakatani, Takayuki Sumiyoshi, Yuki Kita, et al.
Hinyokika Kiyo. Acta Urologica Japonica|September 7, 2011
[A case of renal cell carcinoma associated with paraganglioma]Takayuki Sumiyoshi, Yosuke Shimizu, Takahiro Inoue, et al.
Frontiers in Oncology|September 19, 2025
Case Report: Genomic insights into prostate adenocarcinoma transdifferentiation to carcinosarcoma due to lineage plasticityTomohiro Fukui, Arinobu Fukunaga, Yuki Teramoto, et al.
Frontiers in Oncology|April 17, 2023
Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse modelMasashi Takeda, Hiromasa Sakamoto, Noboru Shibasaki, et al.
Molecular Cancer Therapeutics|May 14, 2026
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiencyYuki Kamiyama, Takuro Sunada, Yutaka Kanoh, et al.
Pageof 8